Seminars in Nuclear Medicine
Volume 39, Issue 4 , Pages 236-246 , July 2009

Genomic Biomarkers for Molecular Imaging: Predicting the Future

  • Mathew L. Thakur, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mathew L. Thakur, PhD, Department of Radiology and Radiation Oncology, Thomas Jefferson University, 1020 Locust Street, Suite 359JAH, Philadelphia, PA 19107

References 

  1. Cho CS. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 2007;6:25–49
  2. Jamel A, Siegel R, Ward E, et al. Cancer statistic. Cancer J Clin. 2007;57:43–66
  3. Adelaide J, Monges G, Derderian C, et al. Oesophageal cancer and amplification of the human cyclin D gene CCND1 /PRAD1. Br J Cancer. 1995;71:64–68
  4. Vande V, Peterseth MJ, Mooi WJ, et al. NeuProtein overexpression in breast cancer (Associates with comedo type ductal carcinoma in situ and limited prognostic value in stage II breast cancer). N Engl J Med. 1988;319:1239–1245
  5. Mukherjee A, Wickstrom E, Thakur M, et al: Imaging oncogene expression. Eur J Radiol (in press)
  6. Gwynne P, Heebner G. Technologies in cancer research: Progress at the molecular level. Science. 2001;291:2183–2203
  7. Raffi S, Lyden D. A few to flip the angiogenic switch. Science. 2008;319:163–164
  8. Fogarty M. Finding ways to starve the cancer seed. Scientist. 2002;41:31–32
  9. Steinberg D. DNA chips track tumor metastasis. Scientist. 2002;41:29–30
  10. Hoffman TJ, Gali H, Smith CJ, et al. Novel series of IIIIn-labelel bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003;44:823–831
  11. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48:1741–1748
  12. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med. 2003;30:417–422
  13. Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the (90)Y-labelled peptide vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med. 2002;29:486–493
  14. Thakur M, Marcus C, Saeed S, et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 2000;41:107–110
  15. Zhang K, Aruva M, Shanthly N, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regul Pept. 2007;144:91–100
  16. Zhang K, Aruva MR, Shanthly N, et al. PET imaging of VPAC1 expression in experimental and spontaneous cancer. J Nucl Med. 2008;49:112–121
  17. Rao PS, Thakur ML, Pallela V, et al. 99mTc labeled VIP analog: Evaluation for imaging colorectal cancer. Nucl Med Biol. 2001;28:445–450
  18. Thakur ML, Marcus CS, Kipper SL, et al. Imaging infection with LeuTech. Nucl Med Commun. 2001;22:513–519
  19. Thakur ML, Marcus CS, Saeed S, et al. Imaging tumors in humans with Tc99m-VIP. Ann NY Acad Sci. 2000;921:37–44
  20. Gottschall PE, Tatsuno I, Miyata A, et al. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology. 1990;127:272–277
  21. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul Pept. 2002;108:165–173
  22. Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP. Receptors Channels. 2002;8:137–153
  23. Le SV, Yamaguchi DJ, McArdle Ca, et al. PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells. Regul Pept. 2002;109:115–125
  24. Germano PM, Le SV, Oh DS, et al. Differential coupling of PAC1 SV1 splice variant of human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2 does not activate tumor proliferation. J Mol Neurosci. 2004;22:83–92
  25. Schulz S, Rocken C, Mawrin C, et al. Immunocytochemical identification of VPAC1, VPAC2 and PAC1 receptors in normal and neoplastic human tissues with subtype specific antibodies. Clin Cancer Res. 2004;10:8234–8242
  26. Reubi JC. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med. 1995;36:1825–1825
  27. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:63–70
  28. Reubi JC, Laderach U, Waser B, et al. Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60:3105–3012
  29. Pallela VR, Thakur ML, Chakder S, et al. Tc99m labeled vasoactive intestinal peptide receptor agonist: Functional studies. J Nucl Med Biol. 1999;40:352–360
  30. Thakur Ml, Aruva M, Bolewska-Pedyczak E, et al. Preparation of Cu-64 and Tc99m-N2S2-vasoactive intestinal peptide (VIP) for imaging gene expression. J Label Compds Radiopharm. 2003;46:S128
  31. Bostwick DG, Murphy G. High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer. 1995;75:1823–1836
  32. Thompson IM, Lucia MS, Redman MW, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007;178:107–109
  33. Hanahan D, Weinberg RA. Hall marks of cancer. Cell. 2000;100:57–70
  34. Tian X, Aruva MR, Zhang K, et al. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu] chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J Nucl Med. 2007;48:1699–1707
  35. Chakrabarti A, Zhang K, Aruva MR, et al. Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biol Ther. 2007;6:948–956
  36. Tian X, Chakrabarti A, Amirkhanov N, et al. Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochem Soc Trans. 2007;35:72–76
  37. Tian X, Chakrabarti A, Amirkhanov NV, et al. External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. Ann NY Acad Sci. 2005;1059:106–144
  38. Tian X, Aruva MR, Wolfe HR, et al. Tumor-targeting peptide-PNA-peptide chimeras for imaging overexpressed oncogene mRNAs. Nucleosides Nucleotides Nucleic Acids. 2005;24:1085–1091
  39. Chakrabarti A, Aruva MR, Sajankila SP. Synthesis of novel peptide nucleic acid-peptide chimera for non-invasive imaging of cancer. Nucleosides Nucleotides Nucleic Acids. 2005;24:409–414
  40. Tian X, Aruva MR, Qin W, et al. Noninvasive molecular imaging of MYC mRNA expression in human breast cancer xenografts with a [99mTc]peptide-peptide nucleic acid-peptide chimera. Bioconjug Chem. 2005;16:70–79
  41. Tian X, Aruva MR, Qin W, et al. External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras. J Nucl Med. 2004;45:2070–2082
  42. Wickstrom E, Tian X, Amirkhanov NV, et al. Radionuclide-peptide nucleic acid in diagnosis and treatment of pancreatic cancer. Methods Mol Med. 2005;106:135–191
  43. Zhang K, Kumar D, Wang C, et al. PET imaging of spontaneous mouse mammary tumor virus (MMTV) infected breast cancer (BC) using Cu-64-TP3805. J Nucl Med. 2009;(in press)
  44. Agarwal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996;14:376–378
  45. Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol. 1987;24:187–202
  46. Aboyul-Fad IT. Antisense oligonucleotides: The state of art. Curr Med Chem. 2005;12:2193–2214
  47. Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer. 2003;41(suppl 1):S81–S88
  48. Tamm I. Antisense therapy in malignant diseases: Status quo and quo vadis?. Clin Sci Lond. 2006;110:427–442
  49. Femino AM, Fay FS, Fogarty K, et al. Visualization of single molecules of mRNA in situ. Methods Enzymol. 2003;361:245–304
  50. Gottifredi V, Prives C. Molecular biology (Getting p53 out of the nucleus). Science. 2001;292:1851–1852
  51. Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol. 2005;18:374–381
  52. Liu S, Edgerton SM, Moore DH, et al. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res. 2001;7:1716–1723
  53. Zhang HF, Maslov K, Stoica G, et al. Functional photoacoustic microscopy for high-resolution and noninvasive in vivo imaging. Nat Biotechnol. 2006;24:848–851
  54. Keren S, Zavaleta C, Cheng Z, et al. Noninvasive molecular imaging of small living subjects using Raman spectroscopy. Proc Natl Acad Sci USA. 2008;105:5844–5849

 Supported by grants from NIHCA 10923, CO27175, EB001809, ISIORR23709, and PAME03184.

PII: S0001-2998(09)00020-8

doi: 10.1053/j.semnuclmed.2009.03.006

Seminars in Nuclear Medicine
Volume 39, Issue 4 , Pages 236-246 , July 2009

Article Tools

* Image Usage & Resolution